



2015-07-07

PRESS RELEASE

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow

New York, July 7, 2015 -- Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed a registration statement on Form F-1/A with the Securities and Exchange Commission, in connection with the proposed public offering of ordinary stock and listing on the NASDAQ Stock Market. The number of American Depositary Shares, representing ordinary shares, to be offered, and the price range for the offering have not yet been determined. An Investor Roadshow will be conducted in the US during July 2015.

Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, which is expected to close on July 30, 2015 at the latest, subject to customary closing conditions.

“This is a very exciting time for Oasmia, as we progress through the final stages of the filing and NASDAQ listing process to create exposure to new financial markets,” said Julian Aleksov, Executive Chairman of Oasmia. “As we establish ourselves on the US market, we believe our potential for growth is significant. We look forward to working together with the many medical professionals and veterinarians to further establish our technology as an innovative and effective means for combatting cancer.”

Oasmia seeks increased visibility within both the pharmaceutical sector and mainstream markets, following what many perceive to be a significant expansion of cancer treatments. Recently, Sorrento Therapeutics has expanded its Cynviloq strategy into multiple cancer indications, potentially receiving over \$1 billion in compensation for rights; further, Abraxane, a treatment similar to Oasmia’s patented product Paclical[®], was acquired for \$2.9 billion by Celgene Inc. Oasmia believes its family of products is positioned for significant sales growth, due to its track record of novel technology, presenting positive clinical data and its product pipeline for new applications.

Following a year where worldwide spending on cancer drugs surpassed \$100 billion, an increase of 10% from 2013, Oasmia anticipates establishing a US-based sales platform for its products. The animal health industry has continued to grow over the past decade¹, reaching nearly \$25 billion in 2014. Specifically, the market for veterinary oncology shows tremendous upside as well, exemplified by the approximately 25% of dogs that will develop a tumor during their lifetime and owners’ increased interest in committing to treatments for their companions.

¹ <http://healthforanimals.org/our-industry/animal-health-industry-global-market-review-2011/>

The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: info@oasmia.com. In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.oasmia.com

For more information, please contact:

Julian Aleksov, Executive Chairman,
Tel: +46 18 50 54 40
E-mail: julian.aleksov@oasmia.com

Anders Lundin, Chief Financial Officer
Mobile: +46 70 20 96 300
E-mail: anders.lundin@oasmia.com

Eric Fischgrund
FischTank Marketing and PR
E-mail: eric@fischtankpr.com

Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08.30, CET on July 7, 2015."